A carregar...

Population Pharmacokinetics of Cariprazine and its Major Metabolites

BACKGROUND AND OBJECTIVES: Cariprazine, a dopamine D(3)-preferring D(3)/D(2) receptor partial agonist, is approved for the treatment of adults with schizophrenia (1.5–6 mg/day) and manic/mixed (3–6 mg/day) episodes associated with bipolar I disorder. This population pharmacokinetic analysis describe...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Eur J Drug Metab Pharmacokinet
Main Authors: Periclou, Antonia, Phillips, Luann, Ghahramani, Parviz, Kapás, Margit, Carrothers, Timothy, Khariton, Tatiana
Formato: Artigo
Idioma:Inglês
Publicado em: Springer International Publishing 2020
Assuntos:
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC7811992/
https://ncbi.nlm.nih.gov/pubmed/33141308
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s13318-020-00650-4
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!